ABSTRACT
OBJECTIVE: Describe malignancy rates in childhood onset and adult onset systemic lupus erythematous (SLE) by proportional meta-analysis. METHODS: Two reviewers screened data from PubMed (1966-2015), EMBASE (1980-2015), and LILACS (1982-2015) for SLE-associated malignancy. Proportional meta-analysis with a random-effects model and 95% confidence intervals (CIs) were calculated according to SLE onset age and mean follow-up time. Statistical difference was defined by 95% CI overlap. RESULTS: Overall the malignancy rate reported in 30 case series with 96,578 subjects was 3.4% (95% CI, 0.0260-0.0442; I = 97.6%; P < 0.0001). The malignancy rate was 4.2% (95% CI, 0.0318-0.0531; I = 98%; P < 0.0001) in 25 adult-onset SLE series, compared with 0.5% (95% CI, 0.0003-0.0154; I = 62.6%; P = 0.03) in 5 childhood-onset SLE series. Overall, in those with less than 5 years' follow-up, the malignancy rate was 2.8% (95% CI, 0.013-0.047; I = 91%; P < 0.0001) compared with 3.6% (95% CI, 0.0226-0.0531; I = 98.3%; P < 0.0001) in those with more than 5 years' follow-up, which was not significant, with 95% CI overlap. CONCLUSIONS: The meta-analysis indicated lower malignancy rates in pediatric-onset SLE compared with adult-onset SLE, but accrued data from childhood-onset SLE are still needed.
Subject(s)
Lupus Erythematosus, Systemic/epidemiology , Neoplasms , Adult , Age of Onset , Child , Humans , Incidence , Neoplasms/classification , Neoplasms/epidemiology , Risk Assessment , Risk FactorsABSTRACT
Os autores fazem uma revisão dos antiinflamatórios não-esteróides, discutindo seu mecanismo de ação e enfocando a discussão sobre os inibidores seletivos da cicloxigenase-2. A experiência clínica e a literatura mostram que os inibidores seletivos da COX-2 representam um importante progresso no tratamento da dor e dos processos inflamatórios.
